OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...

New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...

Presenters highlight clinical insights and lessons from recent trial data and surgical experience On efficacy, Regillo said ...

How equitably are glaucoma medications being dispensed across a universal health care system, and how have prescribing ...

An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...

Initiating aflibercept 8 mg or faricimab as a first-line therapy was associated with longer treatment intervals and superior ...

Bausch + Lomb announced topline results from its phase 2 study of BL1107 in patients with glaucoma. According to the company, ...

A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, ...

REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of ...

Introducing Nicholas Riina, MS. Nicholas Riina, MS, had his eye on the prize early on, growing up in a family in which he was ...

OLN324 outperformed faricimab on anatomic outcomes as early as week 1 in the JADE trial, with no cases of intraocular ...

Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 ...